アミノペンタミド
Aminopentamide
4-(dimethylamino)-2,2-diphenylvaleramide
別名: Centrine · Aminopentamide hydrogen sulfate · Dimevamid
VetSheet 獣医チームが監修更新日 2026年4月5日エビデンスに基づく獣医学リファレンス
用量は獣医専門家向けの臨床参考資料です。必ず最新の医薬品情報および個別症例に基づいて確認してください。
動物種別用量
🌎 NA — North America🌍 EU — Europe
犬
| 適応 | 用量 | 経路 | 頻度 | 期間 | 地域 |
|---|---|---|---|---|---|
| Acute abdominal visceral spasm, nausea, vomiting, diarrhea | 10 lbs or less: 0.1 mg; 11-20 lbs: 0.2 mg; 21-50 lbs: 0.3 mg; 51-100 lbs: 0.4 mg; over 100 lbs: 0.5 mg. If desired effect is not attained, dosage may be gradually increased up to 5 times these amounts. | PO, IM, SC | q8-12h | — | 🌎 NA |
| To decrease tenesmus in malabsorption/maldigestion syndromes | 0.1-0.4 mg (total dose) | SC, IM | BID-TID | — | 🌎 NA |
猫
| 適応 | 用量 | 経路 | 頻度 | 期間 | 地域 |
|---|---|---|---|---|---|
| Acute abdominal visceral spasm, nausea, vomiting, diarrhea | 10 lbs or less: 0.1 mg; 11-20 lbs: 0.2 mg; 21-50 lbs: 0.3 mg; 51-100 lbs: 0.4 mg; over 100 lbs: 0.5 mg. If desired effect is not attained, dosage may be gradually increased up to 5 times these amounts. | PO, IM, SC | q8-12h | — | 🌎 NA |
| Second-line adjunctive therapy for refractory IBD | 0.1-0.4 mg/kg | SC | BID-TID | — | 🌎 NA |
用量は獣医専門家向けの臨床参考資料です。必ず最新の医薬品情報および個別症例に基づいて確認してください。
概要
アミノペンタミドは、犬および猫の急性腹部内臓痙攣、幽門痙攣、肥厚性胃炎、およびそれに伴う悪心、嘔吐、下痢の管理に歴史的に使用されてきた獣医特有の抗コリン薬および鎮痙薬です。
臨床のポイント: かつては一般的でしたが、イレウス（腸閉塞）や全身性の副作用を引き起こすリスクがあるため、非特異的な胃腸の不調に対する全身性抗コリン薬の使用は、現在ではマロピタントやオンダンセトロンなどのより標的を絞った制吐薬や消化管運動機能改善薬にほぼ取って代わられています。
作用機序
Aminopentamide acts as a competitive antagonist at muscarinic acetylcholine receptors (mAChRs) in the parasympathetic nervous system. By blocking acetylcholine binding, it inhibits parasympathetic tone.
- GI Tract: → Decreases smooth muscle contractions (reducing colonic spasms) and reduces gastric acid secretion.
- Systemic: Compared to atropine, it reportedly has a greater targeted effect on reducing colonic contractions with relatively fewer mydriatic (pupil dilating) and salivary (dry mouth) effects, though classic anticholinergic signs can still occur.
安全性・警告
禁忌
- Glaucoma (absolute contraindication)
- Pyloric obstruction
- Hypersensitivity to anticholinergic drugs
- Tachycardias secondary to thyrotoxicosis or cardiac insufficiency
- Myocardial ischemia
- Unstable cardiac status during acute hemorrhage
- GI obstructive disease
- Paralytic ileus
- Severe ulcerative colitis
- Obstructive uropathy
- Myasthenia gravis (unless used to reverse adverse muscarinic effects)
- Known or suspected GI infections (e.g., parvovirus enteritis)
有害事象
- Dry mouth (xerostomia)
- Dry eyes (keratoconjunctivitis sicca)
- Blurred vision (mydriasis)
- Urinary hesitancy or retention
- Tachycardia
- Decreased GI motility (constipation/ileus)
注意事項
Warning: Antimuscarinic agents can decrease GI motility, potentially prolonging the retention of toxins or infectious agents (e.g., parvovirus). Use with extreme caution in these cases.
Use with caution in patients with:
- Hepatic or renal disease
- Hyperthyroidism
- Hypertension
- Congestive Heart Failure (CHF) or tachyarrhythmias
- Prostatic hypertrophy
- Esophageal reflux
- Geriatric or pediatric patients
医薬品相互作用
May enhance the activity of anticholinergic derivatives
May enhance the activity of anticholinergic derivatives
May enhance the activity of anticholinergic derivatives
May enhance the activity of anticholinergic derivatives
May enhance the activity of anticholinergic derivatives
May enhance the activity of anticholinergic derivatives
May potentiate the adverse effects of anticholinergic derivatives
May potentiate the adverse effects of anticholinergic derivatives
May potentiate the adverse effects of anticholinergic derivatives
May increase intraocular pressure
Anticholinergic derivatives may enhance actions
Anticholinergic derivatives may enhance actions
Anticholinergic derivatives may enhance actions
Anticholinergic derivatives may antagonize metoclopramide actions
監視
- Clinical efficacy (resolution of spasms, vomiting, or diarrhea)
- Heart rate (monitor for tachycardia)
- Urination frequency and volume (monitor for urinary retention)
- Eye moisture and pupil size
過剰投与
No specific information was located regarding acute overdosage clinical signs or treatment for aminopentamide. Guidelines for atropine overdose may be applied:
- Decontamination: If recent oral ingestion, empty gut contents and administer activated charcoal and saline cathartics.
- Supportive Care: Treat clinical signs symptomatically. Fluid therapy and standard treatments for shock may be instituted. Do not use phenothiazines as they may contribute to anticholinergic effects.
- Antidote (Severe Cases): The use of physostigmine is controversial and reserved for extreme agitation or life-threatening supraventricular/sinus tachycardias. Human pediatric dose (reasonable for small animals): 0.02 mg/kg slow IV, repeat q10 minutes until reversal of toxic effects. Physostigmine adverse effects (bronchoconstriction, bradycardia, seizures) may be treated with small doses of IV atropine.
製品
製剤
- Tablets
- Injection
動物用医薬品
- Aminopentamide Hydrogen Sulfate Tablets: 0.2 mg; Centrine® (Pfizer)
- Aminopentamide Hydrogen Sulfate Injection: 0.5 mg/mL in 10 mL vials; Centrine® (Pfizer)
規制ステータス
規制データなし: 🇺🇸 US · 🇪🇺 EU · 🇬🇧 UK · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
保管・安定性
Store aminopentamide tablets and injection at controlled room temperature (15-30°C; 59-86°F).
飼主向け情報
アミノペンタミドは胃腸の痙攣を和らげるのに役立ちます。
- 副作用に注意: ペットの口の渇き、目の渇き、または瞳孔の散大が見られる場合があります。
- 重要: この薬は尿閉（尿が出なくなること）を引き起こす可能性があるため、ペットが排尿時にいきんだり、排尿できなかったり、非常に不快そうにしている場合は、すぐに獣医師に連絡してください。
VetSheet医薬品リファレンスは獣医専門家の臨床意思決定支援を目的としており、専門的判断または製造業者の最新医薬品情報の代替にはなりません。